We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ATD:TSXAlimentation Couche-Tard Inc. Analysis

Data as of 2026-03-10 - not real-time

CA$80.88

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Alimentation Couche‑Tard trades at C$80.88, comfortably above its 20‑day (C$82.73), 50‑day (C$77.95) and 200‑day (C$73.47) moving averages, signaling a bullish price environment. The RSI sits near 50 (49.95), indicating neutral momentum, while the MACD histogram is negative, suggesting short‑term bearish pressure but the overall trend remains bullish. Support at C$78.33 and resistance at C$85.59 frame a price corridor that aligns with the projected 10% upside from the DCF model, though the fair‑value estimate of C$23.40 flags a potential overvaluation concern. Volatility over the past 30 days is modest at ~29.7% and beta is low (≈0.27), implying limited price swings relative to the market. Fundamental metrics show a PE of 21.6, forward PE of 18.1, and a dividend yield of 1.06% with a conservative payout ratio of 20%, supporting dividend sustainability. The newly announced Core + More strategy emphasizes organic growth in core fuel, nicotine, and beverage segments while expanding EV‑charging infrastructure in Europe, providing a clear growth narrative through 2030. Analyst consensus remains bullish with a “buy” recommendation and a median target near C$90, reflecting confidence in execution of the strategic plan despite the valuation gap.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price is above key moving averages indicating bullish bias
  • Support level at C$78.33 provides downside cushion
  • MACD histogram negative suggesting limited upside in the near term

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Core + More strategy targeting EBITDA growth through 2030
  • Stable cash flow and low payout ratio support dividend and reinvestment
  • Projected upside of ~10% and favorable analyst price targets

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Diversified global footprint mitigates regional shocks
  • Sustainable dividend with strong free cash flow
  • Valuation appears fair with modest long‑term growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth2.60%
Profit Margin3.60%
P/E Ratio21.6
ROE17.67%
ROA6.15%
Debt/Equity101.32
P/B Ratio3.6
Op. Cash FlowCA$5.2B
Free Cash FlowCA$2.3B

Technical Analysis

TrendBullish
RSI49.9
SupportCA$78.33
ResistanceCA$85.59
MA 20CA$82.73
MA 50CA$77.95
MA 200CA$73.47
MACDBearish
VolumeStable
Fear & Greed Index78.41

Valuation

Fair ValueCA$23.40
Target PriceCA$89.70
Upside/Downside10.91%
GradeFair
TypeBlend
Dividend Yield1.06%

Risk Assessment

Beta0.27
Volatility29.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.